Stock market today: S&P 500 ends flat on fresh trade war worries
On Tuesday, TD Cowen maintained a Hold rating on Sanofi (NASDAQ: NASDAQ:SNY) shares with a consistent price target of $67.00. Currently trading at $52.89, the stock shows potential upside according to InvestingPro analysis, which indicates the stock is currently undervalued. The firm’s analyst, following a recent meeting with Sanofi’s CFO in New York, conveyed a neutral stance on the pharmaceutical company’s stock.
During the meeting, which took place last Friday, the discussions centered on three main topics: forthcoming product-related announcements, Sanofi’s mid-term financial projections, and the broader macroeconomic outlook, including considerations such as tariffs and the Multifiber Arrangement (MFA). With a robust financial health score of 3.09 (rated as "GREAT" by InvestingPro), the company maintains a strong market position.
Sanofi expressed high confidence in meeting its guidance for Dupixent, its leading product, stating competition is not a current worry and loss of exclusivity (LOE) is not expected to pose a significant threat until post-2031. The company also communicated a positive surprise regarding the approval of its Covid vaccine Biologics License Application (BLA) and continues to see its COVID/Flu combination vaccine as a valuable asset.
Additionally, Sanofi anticipates growth for Beyfortus, its respiratory syncytial virus (RSV) monoclonal antibody, expecting it to achieve significant market share and peak sales of €2 billion to just under €3 billion in the near term, despite facing competitive pressures. The company projects that RSV monoclonal antibodies could capture approximately 80% of the market share at their peak, with substantial growth expected in 2025-26. With current annual revenue of $48.9 billion and a market cap of $128.8 billion, detailed financial analysis and growth projections are available in the comprehensive Pro Research Report on InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.